How do I make treatment decisions when facing uncertainty with Colorectal Cancer

Making Treatment Decisions with Colorectal Cancer: A Guide to Navigating Uncertainty

Facing colorectal cancer treatment decisions is genuinely difficult, especially when there are multiple options or unclear paths forward. Here's how to approach this thoughtfully:

Understanding the Decision-Making Framework

Doctors use a structured approach to help guide treatment choices. According to the NCCN Guidelines for Colon Cancer, your care team considers several key factors:

1. Your cancer's stage and characteristics - How deep the tumor penetrates, how many lymph nodes are involved, and whether it has spread
2. Biomarker status - Specific genetic features of your cancer (like MSI/MMR status, KRAS mutations, BRAF mutations) that determine which treatments will work best
3. Your overall health - Age, other medical conditions, and ability to tolerate treatment side effects
4. Your personal values - What matters most to you regarding quality of life, treatment intensity, and outcomes

Key Biomarkers That Shape Treatment Decisions

The NCCN Guidelines emphasize that determining MSI and MMR status at diagnosis is critical because treatment recommendations can vary considerably based on these results. Your pathology report should include:

• Mismatch repair (MMR) status - Whether your cancer has deficient MMR (dMMR) or proficient MMR (pMMR)
• Microsatellite instability (MSI) - Whether your cancer shows MSI-high (MSI-H) or microsatellite stable (MSS) patterns
• Other mutations - KRAS, NRAS, BRAF, HER2, and PIK3CA status

Why this matters: These biomarkers determine whether immunotherapy, targeted therapy, or traditional chemotherapy is most likely to help you.

The Multidisciplinary Approach

The NCCN Guidelines stress that a multidisciplinary approach is necessary for managing colorectal cancer. This means your care team should include:

• Surgical oncologist
• Medical oncologist
• Pathologist
• Radiation oncologist (if relevant)
• Gastroenterologist
• Nurse coordinators and social workers

This team approach reduces uncertainty because multiple specialists review your case and contribute their expertise.

When Uncertainty Is Greatest: High-Risk Stage II Disease

One area where uncertainty commonly arises is stage II colon cancer with high-risk features. According to NCCN Guidelines, doctors consider:

• Poorly differentiated histology (cancer cells look very abnormal)
• Lymphatic or vascular invasion (cancer in blood vessels)
• Bowel obstruction at diagnosis
• Fewer than 12 lymph nodes examined
• Perineural invasion (cancer in nerve tissue)
• Tumor budding (cancer cells breaking away from the main tumor)

Important context: The NCCN Guidelines note that "the benefit of adjuvant chemotherapy does not improve survival by more than 5%." This means for some patients with stage II disease, the decision to add chemotherapy after surgery is genuinely uncertain—the benefit is modest, and side effects are real.

Questions to Ask When Facing Uncertainty

When your care team presents options, ask these specific questions:

1. "What is my cancer's stage, and what does that tell us about my prognosis?"

   • Request a clear explanation of TNM staging (Tumor, Node, Metastasis)

2. "What are my cancer's biomarkers, and how do they affect treatment options?"

   • Ask specifically about MSI/MMR, KRAS, NRAS, BRAF, and HER2 status
   • Ask how these results change your treatment recommendations

3. "What are the pros and cons of each treatment option for MY specific situation?"

   • Don't accept generic answers—ask how the data applies to your stage and biomarkers
   • Ask about survival benefit vs. side effects for each option

4. "If I choose observation instead of chemotherapy, how will you monitor me?"

   • According to NCCN Guidelines, surveillance includes CEA blood tests, CT scans, and colonoscopy
   • Ask about the schedule and what findings would prompt treatment

5. "Are there clinical trials available for my stage and biomarker profile?"

   • The NCCN Guidelines note that "the Panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy"
   • Clinical trials may offer newer options with better outcomes

6. "What happens if the first treatment doesn't work or stops working?"

   • Ask about second-line and third-line options
   • Understanding the full treatment pathway reduces anxiety about uncertainty

7. "How will we know if treatment is working?"

   • Ask about specific markers (CEA levels, imaging findings) that indicate response
   • Ask about the timeline for reassessing treatment effectiveness

Managing Uncertainty: Practical Strategies

1. Get a Second Opinion

• This is standard practice and helps confirm recommendations
• Bring your pathology report and imaging to the second opinion appointment

**2. Request Your Complete [ID removed]

• You have a legal right to your pathology report, imaging reports, and test results
• Having these in hand helps you understand your situation and ask better questions

3. Understand the Evidence

• Ask your doctor: "What studies support this recommendation?"
• Ask: "How strong is the evidence?" (Is it based on large randomized trials or smaller studies?)

4. Consider Your Values

• Some patients prioritize aggressive treatment to maximize survival chances
• Others prioritize quality of life and prefer less intensive approaches
• Neither choice is "wrong"—it depends on what matters to you

5. Use Decision Aids

• Ask your care team if they have decision support tools or patient education materials
• Some cancer centers offer shared decision-making programs

Special Consideration: Metastatic Disease

If you have metastatic colorectal cancer (cancer that has spread), the NCCN Guidelines describe treatment as "a continuum of care in which lines of treatment are blurred rather than discrete." This means:

• Treatment isn't rigidly divided into "first-line," "second-line," etc.
• Your doctor should have pre-planned strategies for adjusting therapy based on how you respond
• Multiple treatment options exist (chemotherapy, immunotherapy, targeted therapy, biologic agents)
• The goal is to find the approach that works best for your specific cancer

The Role of Surveillance and Monitoring

After treatment, uncertainty often shifts to: "How do I know if my cancer is coming back?" According to NCCN Guidelines, post-treatment surveillance includes:

• CEA blood tests - Every 3-6 months for 2 years, then every 6 months for 5 years (if you're a candidate for further intervention)
• CT scans - Periodic imaging of chest, abdomen, and pelvis
• Colonoscopy - At 1 year after surgery, then based on findings
• Survivorship plan - To manage long-term side effects and promote healthy lifestyle

This structured approach reduces uncertainty by giving you clear markers to watch and a defined follow-up schedule.

When to Seek Additional Support

Consider asking for referrals to:

• Genetic counselor - If you have family history of colorectal cancer or meet criteria for hereditary cancer syndromes
• Palliative care specialist - Not just for end-of-life care, but for managing side effects and quality of life throughout treatment
• Oncology social worker - For practical support, financial resources, and emotional coping
• Nutritionist - To optimize nutrition during and after treatment

---

Key Takeaway

Uncertainty in cancer treatment is normal and expected. The goal isn't to eliminate all uncertainty—that's impossible—but to:

1. Understand your specific cancer (stage, biomarkers, prognosis)
2. Know what treatment options exist and why your doctor recommends one
3. Understand the evidence supporting each option
4. Align treatment decisions with your personal values
5. Have a clear plan for monitoring and adjusting treatment if needed

Your oncology team should welcome these questions and help you move from uncertainty to informed confidence in your treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.